Assessment of serum C reactive protein (CRP) levelsin 48 subjects participating in this melanoma trial showed that those on thecombined regimen had a greater than 30% decrease in this proinflammatorymarker, suggesting that the anti-inflammatory effects of the drug combinationmay account for the improvement in progression-free survival. The gene discussed is CRP; the disease is melanoma.